| Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines G Cohen, P Jungsomsri, J Sangwongwanich, K Tawinprai, ... Human Vaccines & Immunotherapeutics 18 (5), 2052525, 2022 | 17 | 2022 |
| Safety after BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescents aged 10–17 years in Thailand S Thonginnetra, K Tawinprai, K Niemsorn, P Promsena, M Tandhansakul, ... Vaccines 10 (10), 1765, 2022 | 14 | 2022 |
| Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population K Tawinprai, T Siripongboonsitti, T Porntharukchareon, B Dechates, ... Human Vaccines & Immunotherapeutics 18 (1), 2035573, 2022 | 14 | 2022 |
| Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine V Rangsrisaeneepitak, T Porntharukchareon, B Dechates, ... Diabetology international 13 (4), 637-643, 2022 | 13 | 2022 |
| Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers … K Tawinprai, T Siripongboonsitti, T Porntharukchareon, K Wittayasak, ... Vaccine 40 (12), 1761-1767, 2022 | 13 | 2022 |
| Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label … T Siripongboonsitti, T Ungtrakul, K Tawinprai, T Nimmol, M Buttakosa, ... International Journal of Infectious Diseases 134, 211-219, 2023 | 9 | 2023 |
| Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12 to 17 years in the Thai population: an Immunobridging study K Tawinprai, T Siripongboonsitti, T Porntharukchareon, P Vanichsetakul, ... Vaccines 10 (5), 807, 2022 | 6 | 2022 |
| Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study … T Siripongboonsitti, T Ungtrakul, K Tawinprai, C Auewarakul, ... Phytomedicine 119, 155018, 2023 | 5 | 2023 |
| Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 … T Siripongboonsitti, N Nontawong, K Tawinprai, O Suptawiwat, ... Microbiology Spectrum 11 (6), e03257-23, 2023 | 4 | 2023 |
| Favipiravir treatment in non-severe COVID-19: promising results from multicenter propensity score-matched study (FAVICOV) T Siripongboonsitti, M Muadchimkaew, K Tawinprai, O Issaranon, ... Scientific Reports 13 (1), 14884, 2023 | 4 | 2023 |
| Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated … K Tawinprai, T Siripongboonsitti, T Porntharukchareon, K Wittayasak, ... Expert Review of Vaccines 21 (12), 1873-1881, 2022 | 4 | 2022 |
| Effect of inactivated SARS-CoV-2 vaccines and ChAdOx1 nCoV-19 vaccination to prevent COVID-19 in Thai households (VacPrevent trial) M Muadchimkaew, T Siripongboonsitti, S Wongpatcharawarakul, ... International Journal of Infectious Diseases 124, 190-198, 2022 | 4 | 2022 |
| The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study T Porntharukchareon, W Chartisathian, M Navinpipat, C Samdaengpan, ... Human Vaccines & Immunotherapeutics 19 (2), 2251850, 2023 | 3 | 2023 |
| The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study N Nontawong, T Siripongboonsitti, K Tawinprai, M Boonpratoom, ... Annals of Clinical Microbiology and Antimicrobials 21 (1), 51, 2022 | 3 | 2022 |
| Telehealth for diabetes care during coronavirus disease 2019 pandemic T Porntharukchareon, S Worawichawong, K Tawinprai Asia Pacific Journal of Public Health 34 (4), 459-462, 2022 | 3 | 2022 |
| Herpes zoster after COVID-19 vaccination in an adolescent S Thonginnetra, P Limtanyakul, K Tawinprai Dermatology Online Journal 28 (4), 2022 | 3 | 2022 |
| The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective … T Siripongboonsitti, K Tawinprai, K Cheirsilpa, T Ungtrakul, W Krisorakun, ... Medicina 59 (6), 1098, 2023 | 2 | 2023 |
| Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study K Tawinprai, P Jungsomsri, O Pinijnai, F Tavonvunchai, A Lievjaroen, ... Human Vaccines & Immunotherapeutics 19 (1), 2206360, 2023 | 2 | 2023 |
| The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) T Siripongboonsitti, K Tawinprai, P Payoong, N Mahanonda Journal of Infection and Public Health 16 (12), 2010-2016, 2023 | 1 | 2023 |
| Immune response to CoronaVac and its safety in patients with type 2 diabetes compared with healthcare workers B Dechates, T Porntharukchareon, S Sirisreetreerux, P Therawit, ... Vaccines 11 (3), 684, 2023 | 1 | 2023 |
